Orbsen Therapeutics Nominees DAC

Orbsen Therapeutics Nominees Designated Activity Company is a pioneering life‑sciences firm dedicated to “redefining cell therapy”. Drawing on its proprietary platform, the company develops mesenchymal stromal cell products that aim to address some of the most pressing complications of diabetes and related disorders. Its flagship candidate, ORBCEL™, is currently being evaluated in the NEPHSTROM proof‑of‑concept study for patients with diabetes and advanced chronic kidney disease, while additional clinical programmes target diabetic foot disease and primary sclerosing cholangitis.

The pipeline reflects a clear focus on therapies that can halt or reverse organ damage, with early‑stage trials already underway across four European Union sites. Orbsen is also advancing a specialised trial to tackle the leading cause of death among COVID‑19 patients, underscoring its commitment to rapid, translational research. Recent fundraising efforts are supporting the progression to Phase II and Phase IIb studies, positioning the company at the forefront of regenerative medicine.